Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
add, Addendum, air, airflow, alloreactive, alongside, appeal, appointed, appointing, appointment, Arcellx, argument, Asian, AstraZeneca, bathroom, BCM, black, box, boxed, breakdown, Cabaletta, CARGO, Cartesian, Circuit, clarity, consumption, database, debilitating, delisted, deprioritize, derecognized, destination, diverging, docketed, draught, easily, electric, embodying, energy, ethnic, Excellence, exterior, extrarenal, familiar, FDIC, fifty, figure, footprint, frequency, Guarino, Hawaiian, Hispanic, hour, IDTA, inflamed, installed, intrusion, investor, Islander, Israel, Kyverna, language, LBCL, lending, lock, lodge, mindful, misclassify, mismanagement, mission, misuse, moiety, momentum, moot, motion, myasthenia, Native, NV, older, onboarding, opine, outfitted, outsourced, Pacific, pathophysiology, penetrating, plaintiff, plant, Poseida, presidential, proceed, racial, receivership, Rescue, robustly, RTOR, sample, Sana, Sandborn, sentiment, Shield, Signature, Silvergate, SLE, SLT, smart, stakeholder, steady, stifled, sublease, subtenant, successor, supervisory, swept, theft, thereunder, thirty, threat, tighter, trailblazing, trustee, unapproved, undetected, Undisclosed, undrawn, unified, unjust, unresponsive, upcoming, vehicle, VGPR, water, William, withstand, Wolchko, worth
Removed:
activating, adult, advocate, amending, assigned, Atara, attaining, automatic, beta, bifurcated, biology, breast, build, bundle, called, ceased, cetuximab, characterization, chemotactic, classify, close, Codification, colorectal, commandeered, Composite, Conditionally, confidence, constant, constrained, continuously, contractor, corroborative, COSO, cryopreservation, customary, detect, deteriorate, disposition, distancing, distinguished, distinguishing, DNA, efficiently, eighteen, element, embedded, enabling, epidemic, equally, equipped, ESPP, existed, exploit, flowing, follicular, fourth, gamma, gastric, graph, headcount, histocompatibility, home, hypothetical, immunity, immunological, innate, inside, inspected, instrument, Intellia, interact, interferon, Iovance, IPO, jointly, landlord, leaving, LIBOR, lung, lymphocytic, mature, measure, movement, MSK, mutual, neck, nominated, nomination, object, occurring, orally, orchestrating, output, participant, pattern, pertain, positively, potentiate, preceding, precursor, preemptive, proactive, proinflammatory, proportional, quarantine, rearrange, rearrangement, recoverability, redeemable, region, relapse, releasing, remotely, repay, residing, Sanofi, satisfying, seasoned, secrete, sensitivity, shareholder, ship, situation, stay, successive, supporting, suppressed, tenant, termed, thereon, transformation, transition, transplant, underwriting, unharmed, unqualified, York
Filing tables
Filing exhibits
Related press release
Associated FATE transcripts
FATE similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
1.
Registration Statements (Form S-3 Nos. 333-213590, 333-215460, 333-219987, 333-260772 and 333-275402) of Fate Therapeutics, Inc., and
2.
Registration Statements (Form S-8 Nos. 333-191576, 333-194625, 333-202690, 333-209392, 333-211484, 333-215880, 333-219989, 333-223521, 333-230152, 333-236835, 333-253459, 333-263102 and 333-265502) pertaining to the 2007 Equity Incentive Plan, the 2013 Stock Option and Incentive Plan, the 2013 Employee Stock Purchase Plan, the Inducement Equity Plan and the 2022 Stock Option and Incentive Plan of Fate Therapeutics, Inc.;
of our report dated February 26, 2024, with respect to the consolidated financial statements of Fate Therapeutics, Inc. included in this Annual Report (Form 10-K) of Fate Therapeutics, Inc. for the year ended December 31, 2023.
/s/ Ernst & Young LLP
San Diego, California
February 26, 2024